XML 27 R16.htm IDEA: XBRL DOCUMENT v3.25.2
EARNINGS (LOSS) PER SHARE
 6 Months Ended
Jun. 30, 2025
Earnings Per Share [Abstract]  
EARNINGS (LOSS) PER SHARE

NOTE 8 – EARNINGS (LOSS) PER SHARE

 

Basic earnings (loss) per common share (“EPS”) is based on the weighted average number of common shares outstanding during each period presented. Shares of unissued vested restricted stock units (“RSUs”) and restricted stock awards (“RSAs”) are included in our calculation of basic weighted average common shares outstanding. Unvested RSUs and RSAs, convertible securities, warrants and options to purchase common stock are included as common stock equivalents only when dilutive. Potential common stock equivalents are excluded from diluted earnings per share when the effects would be antidilutive.

 

The Company follows the provisions of ASC 260, Diluted Earnings per Share. In computing diluted EPS, basic EPS is adjusted for the assumed issuance of all potentially dilutive securities. The dilutive effect of call options, warrants and share-based payment awards is calculated using the “treasury stock method,” which assumes that the “proceeds” from the exercise of these instruments are used to purchase common shares at the average market price for the period. The dilutive effect of traditional convertible debt and convertible preferred stock is calculated using the “if-converted method.” Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting common shares are included in the denominator of the diluted EPS calculation for the entire period being presented.

 

The following table sets forth the computation of basic and diluted earnings (loss) per share:

 

   2025   2024   2025   2024 
   Three Months Ended June 30,   Six Months Ended June 30, 
   2025   2024   2025   2024 
Numerator:                
Net loss attributable to LifeMD, Inc. common stockholders - basic  $(2,851,436)  $(7,652,202)  $(2,243,195)  $(15,197,120)
Adjustment   -    -    -    - 
Net loss attributable to LifeMD, Inc. common stockholders - diluted  $(2,851,436)  $(7,652,202)  $(2,243,195)  $(15,197,120)
                     
Denominator:                    
Weighted average number of common shares outstanding - basic   44,401,531    41,296,042    43,772,151    40,269,139 
Adjustment for the potential dilutive common shares   -    -    -    - 
Weighted average number of common shares outstanding - diluted   44,401,531    41,296,042    43,772,151    40,269,139 
                     
Basic loss per share attributable to LifeMD, Inc. common stockholders  $(0.06)  $(0.19)  $(0.05)  $(0.38)
Diluted loss per share attributable to LifeMD, Inc. common stockholders  $(0.06)  $(0.19)  $(0.05)  $(0.38)

 

Basic loss per share is the same as diluted net loss per share attributable to common stockholders for the three and six months ended June 30, 2025 and 2024, because the inclusion of potential shares of common stock would have been anti-dilutive.

 

The following table discloses the securities that were not included in the computation of diluted net earnings (loss) per share as their inclusion would have been anti-dilutive:

  

   2025   2024   2025   2024 
   Three Months Ended June 30,   Six Months Ended June 30, 
   2025   2024   2025   2024 
RSUs and RSAs   1,933,014    2,279,750    1,582,467    2,296,125 
Stock options   437,544    1,527,000    424,941    1,843,375 
Warrants   1,024,809    1,743,730    971,327    2,068,419 
Convertible long-term debt   671,141    671,141    671,141    671,141 
Total   4,066,508    6,221,621    3,649,876    6,879,060